Palliative Care: Clinical Trials

47 trials of Palliative Care, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

26 completed, 10 recruiting, 6 unknown, 3 terminated. 47 Phase 2, 13 Phase 1, 10 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 247Completed 26, Recruiting 10, Unknown 6, Terminated 3, Not yet recruiting 1, Withdrawn 1
Phase 113Completed 7, Recruiting 5, Unknown 1
Phase 310Completed 3, Unknown 3, Recruiting 2, Terminated 2

Follow Palliative Care: new trials by email Literature Review of Palliative Care trials Research Report on Palliative Care

Trials (filtered) newest first · largest first

All 47 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Partner4Exercise Study
Peer matching, Quailfied Exercise Professional (QEP) Support - Cancer
Phase 2 / Phase 3RecruitingMcMaster University1832026-09-012026-10-29
Psilocybin-Assisted Therapy
psilocybin, Supportive Therapy, Prolonged Exposure Therapy - PTSD
Phase 2RecruitingEmory University1502026-06-082026-10-01
Dual-Target CAR-NK Cells Targeting MSLN, EGFR, or HER2 in Advanced NSCLC
Dual-target CAR-NK cells, Lymphodepleting chemotherapy, Supportive care - Non-Small Cell Lung Cancer, Advanced/Metastatic
Phase 1 / Phase 2RecruitingBeijing Biotech602026-03-022026-06-11
Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16) pt2
Dual-target CAR-NK cell product, Cyclophosphamide, supportive - Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma
Phase 1 / Phase 2RecruitingBeijing Biotech362026-03-022026-06-01
Dual-Target CAR-NK Cells Directed Against MSLN, EGFR, or HER2 in Advanced NSCLC
Dual-target CAR-NK cells, Lymphodepleting chemotherapy, Supportive Care - Non-Small Cell Lung Cancer, Advanced/Metastatic NSCLC
Phase 1 / Phase 2RecruitingBeijing Biotech482026-02-022026-03-12
Dual-Target CAR-NK Cells for Advanced Breast Cancer HER2+ TNBC
Dual-target CAR-NK cells, Lymphodepleting, Supportive care - Breast Cancer (Advanced/Metastatic), HER2-positive Breast Cancer
Phase 1 / Phase 2RecruitingBeijing Biotech602026-02-022026-04-06
Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC)
Dual-target CAR-NK cells (EB-DT-CAR-NK), Lymphodepleting chemotherapy, Supportive care - Breast Cancer (Locally Advanced or Metastatic), HER2-positive Breast Cancer
Phase 1 / Phase 2RecruitingBeijing Biotech602026-02-022026-03-20
Ambulatory Oxygen Therapy for Individuals With Mild-to-moderate Interstitial Lung Disease
Exertional Oxygen, Education and Support - Fibrotic Interstitial Lung Disease
Phase 2RecruitingUniversity of Alberta602025-07-012026-11-05
Tetra-modality Bladder Preservation Strategies in Muscle-invasive Bladder Cancer: TURBT+ Chemo/Immunotherapy+ Radiation Therapy+ Maintenance Immunotherapy vs. W&W
Maximum TURBT, Chemotherapy + Immunotherapy Induction, Radiotherapy - Muscle-invasive Bladder Cancer
Phase 2RecruitingAmerican University of Beirut Medical Center802025-06-112026-10-29
A Study of Amantadine for Cognitive Dysfunction in Patients With Long-Covid
Amantadine, Physical, Occupational, Speech Therapy, Provider Counseling - Long COVID, Post-Acute COVID-19 Syndrome
Phase 2WithdrawnUniversity of Texas Southwestern Medical Center2025-06-012025-08-26
Evaluating the Benefits of Personalized Traditional Chinese Medicine in Postoperative Treatment for Locally Advanced Colorectal Cancer
Adjuvant Chemotherapy Combined with Traditional Chinese Medicine (TCM) Supportive Therapy - Locally Advanced Colorectal Cancer, Postoperative Adjuvant Therapy
Phase 2Not yet recruitingSir Run Run Shaw Hospital802024-10-012024-09-19
Enhancing Work Participation of Unemployed and Work-Disabled Cancer Survivors
PLACES - Cancer Survivors, Return to Work
Phase 2 / Phase 3UnknownAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)1642023-09-012023-09-29
Switch-Maintenance Gemcitabine After First-Line Chemotherapy In Patients With Malignant Pleural Mesothelioma
Gemcitabine, supportive care - Malignant Pleural Mesothelioma
Phase 2CompletedAin Shams University402023-04-012024-08-27
The Use of Eltrombopag Post HSCT in BMFD
Eltrombopag 25 MG Oral Tablet, Supportive care - Stem Cell Transplant Complications
Phase 2 / Phase 3CompletedThe First Affiliated Hospital of Soochow University1182022-10-222025-12-03
AZA + Venetoclax as Maintenance Therapy in Younger Adults With AML in First Remission
Azacitidine, Venetoclax, Supportive care - Acute Myeloid Leukemia (AML) in Remission
Phase 2 / Phase 3RecruitingThe First Affiliated Hospital of Soochow University1242022-06-252022-08-19
Avatrombopag to Promote Platelet Engraftment After Allo-HSCT
Avatrombopag, Supportive care - Platelet Disorder
Phase 2UnknownThe First Affiliated Hospital of Soochow University202021-12-012022-12-23
Molecular Profiling and Matched Targeted Therapy for Patients With Unresectable Advanced or Metastatic Melanoma
Standard therapy or clinical trial, Matched targeted therapy, Trametinib and / or supportive care - Melanoma
Phase 2CompletedMelanoma Institute Australia2162021-11-222026-05-29
Mesenchymal Stromal Cells for the Treatment of SARS-CoV-2 Induced Acute Respiratory Failure (COVID-19 Disease)
Mesenchymal Stromal Cells, Supportive Care - Sars-CoV2, Acute Respiratory Distress Syndrome
Phase 1 / Phase 2CompletedBaylor College of Medicine282021-02-122026-10-21
Covid-19 Infection and Pulmonary Distress Treatment With Zanubrutinib in Hospitalized Participants
Zanubrutinib, Supportive Care, Placebo - COVID-19 Pulmonary Complications, COVID-19
Phase 2CompletedBeiGene632020-07-062024-10-26
Efficacy of Convalescent Plasma Therapy in Severely Sick COVID-19 Patients
Convalescent Plasma Transfusion, Supportive Care, Random Donor Plasma - COVID
Phase 2CompletedInstitute of Liver and Biliary Sciences, India292020-04-202020-06-12

Showing 20 of 47. Sign in to see all of them.

Conditions studied

Carcinoma, Non-Small-Cell Lung (3)  ·  Depression (3)  ·  Neoplasm Metastasis (3)  ·  Stress Disorders, Post-Traumatic (3)  ·  Thrombocytopenia (3)  ·  Bipolar Disorder (2)  ·  Breast Neoplasms (2)  ·  COVID-19 (2)  ·  Carcinoma, Hepatocellular (2)  ·  Colorectal Neoplasms (2)  ·  Heart Failure (2)  ·  Leukemia, Myeloid, Acute (2)  ·  Mental Disorders (2)  ·  Neoplasms (2)  ·  Pain (2)

Sponsors

Beijing Biotech (5)  ·  The First Affiliated Hospital of Soochow University (3)  ·  King's College London (2)  ·  Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (1)  ·  Ain Shams University (1)  ·  All India Institute of Medical Sciences (1)  ·  American University of Beirut Medical Center (1)  ·  Annie Im, M.D. (1)  ·  Arizona State University (1)  ·  Baylor College of Medicine (1)  ·  BeiGene (1)  ·  Beth Israel Deaconess Medical Center (1)  ·  Brigham and Women's Hospital (1)  ·  Centre Oscar Lambret (1)  ·  Clifford Hospital, Guangzhou, China (1)

Countries

United States (17)  ·  China (11)  ·  Canada (2)  ·  India (2)  ·  Australia (1)  ·  Bangladesh (1)  ·  Brazil (1)  ·  Denmark (1)  ·  Egypt (1)  ·  France (1)  ·  Germany (1)  ·  Kenya (1)  ·  Lebanon (1)  ·  Netherlands (1)  ·  Singapore (1)

Top investigators

Abanoub Samir (1)  ·  Alex Menzies (1)  ·  Amy Mathews, M.D. (1)  ·  Anna Wise, PhD (1)  ·  Annie Im, MD (1)  ·  Arthur J. Barsky, MD (1)  ·  Brian Fallon, MD (1)  ·  Depei Wu, PhD,MD (1)  ·  Douglas W. Woods, PhD (1)  ·  Elizabeth W. Twamley, PhD (1)  ·  Helen Heslop, MD (1)  ·  Irene J Higginson, BMBS FRCP FFPHM PhD (1)  ·  James R. Rodrigue, PhD (1)  ·  Jeffrey Cully, PhD MEd BS (1)

Results publications

PMID 11174237, PMID 11309435, PMID 11837876, PMID 17058754, PMID 18215105, PMID 18507817, PMID 19833477, PMID 20358414, PMID 21411144, PMID 21978993, PMID 22868933, PMID 23024246, PMID 23130740, PMID 24001701, PMID 24144615, PMID 25187211, PMID 25271779, PMID 25988365, PMID 26423375, PMID 26631085, PMID 26763495, PMID 26785798, PMID 26908586, PMID 27724833, PMID 28069021, PMID 28202705, PMID 28606503, PMID 28659038, PMID 28846584, PMID 29029679, PMID 29316883, PMID 29480043, PMID 29590544, PMID 29729555, PMID 30790469, PMID 33002633, PMID 33178737, PMID 33987095, PMID 34013969, PMID 34376578, PMID 35522399, PMID 36734509, PMID 36856579, PMID 37142273, PMID 37162745, PMID 38258329, PMID 38330639, PMID 38761558, PMID 39252084, PMID 39906744

NIH funding

2009 (1), R01CA227092 (1), R01DK072325 (1), R01MH069877 (1), R01MH071688 (1), R01MH072591 (1), R01MH080150 (1), R01MH080966 (1), R21DK077322 (1)